Rani Therapeutics Holdings Inc. Class A (RANI)
NASDAQ: RANIHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
RANI stock chart
Technical analysisKey statistics
All statistics- Market cap
- $59.03M
- EPS (TTM)
- -$0.06
- Dividend yield
- None
- 52-week range
- 0.502 – 1.69
- Day range
- 0.5101 – 0.5819
- Volume / Avg
- 457.42K / 545.67K
- Beta
- —
- Shares outstanding
- 115.49M
52-week range
RANI stock today
On Nov 20, RANI ended the session at $0.5111, shedding $0.0695 (11.97%), versus the S&P 500's 3.70% decline. At this level, RANI sits near the bottom of its 52-week range of $0.502 to $1.69: 69.8% below the high, set on Nov 21, 2025 and 1.8% above the low. RANI is down 62.1% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 68.6%.
Rani Therapeutics has posted a net loss over the last twelve months (EPS of -$0.06), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Rani Therapeutics
Company profileRani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Talat Imran
- Headquarters
- San Jose, CA
- Employees
- 69
- IPO year
- 2021
- Website
- ranitherapeutics.com
Financial highlights
Full financialsIn fiscal 2025, Rani Therapeutics generated $1.6 million in revenue, up 58.9% from fiscal 2024, its 2nd consecutive year of revenue growth. Rani Therapeutics reported a net loss of $29.7 million, compared with a loss of $30.0 million a year earlier. Operating margin was -2346.0%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $1.63M | $1.03M | $0 | $0 | $2.72M |
| Growth | +58.85% | — | — | -100.00% | +488.10% |
| Net income | $-29.67M | $-30.02M | $-33.97M | $-30.59M | $-8.33M |
| EPS (diluted) | $-0.45 | $-1.05 | $-1.33 | $-1.28 | $-0.43 |
Analyst forecast
ForecastConsensus (5 analysts)
strong_buy
Avg. price target
$7.20+1308.73%
- Strong buy 1
- Buy 4
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 9, 2026
- EPS actual vs est.
- $-0.04 vs $-0.05
- Surprise
- +20.00%
RANI news
All RANI news- Rani Therapeutics Holdings, Inc. Reports Third Quarter 2026 Financial Results and FDA Emerging Technology Program AcceptanceNasdaq
- Rani Therapeutics Reports Third Quarter 2026 Financial Results; Provides Corporate UpdateGlobeNewswire
- Rani Therapeutics to Participate in the Chardan Healthcare ConferenceGlobeNewswire
Rani Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| TENXTenax Therapeutics Inc. | 1.25 | -10.07% | $56.92M | vs RANI |
| IBIOiBio Inc. | 0.8001 | -0.11% | $56.37M | vs RANI |
| KZIAKazia Therapeutics Limited ADR | 4.92 | -8.38% | $56.22M | vs RANI |
| VTVTvTv Therapeutics Inc. Class A | 15.51 | -5.20% | $62.22M | vs RANI |
| AZRAzora Therapeutics Inc. | 3.85 | -0.52% | $55.00M | vs RANI |
| BOLDBoundless Bio Inc. | 2.32 | -2.52% | $54.78M | vs RANI |
| FBIOFortress Biotech Inc. | 1.90 | +7.34% | $64.11M | vs RANI |
| XLOXilio Therapeutics Inc. | 7.56 | -1.11% | $53.40M | vs RANI |
Indexes, lists and sector
Rani Therapeutics stock FAQ
What is Rani Therapeutics's stock price today?
RANI last traded at $0.5111 as of Nov 20, 4:00 PM EST, down 11.97% on the day. Prices are delayed at least 15 minutes.
Who is Rani Therapeutics's CEO?
Mr. Talat Imran is the chief executive officer of Rani Therapeutics Holdings Inc. Class A, which has about 69 employees.
What is the RANI 52-week high?
The 52-week high for RANI is $1.69 and the 52-week low is $0.502. The stock is currently 69.8% below its high.